Exclusive: Charles Fuchs departs Roche to become Chief Medical Officer at Tubulis, steering ADC pipeline after $401M Series C
Tubulis has appointed Charles Fuchs, MD as its new Chief Medical Officer (CMO), based in the company’s U.S. office in Cambridge.1
Fuchs previously served as Senior Vice President and Global Head of Oncology & Hematology Product Development at Roche and Genentech, overseeing global oncology and hematology programs and multiple drug approvals.1
At Tubulis, Fuchs will provide strategic clinical and medical leadership as the company advances its most-advanced antibody-drug conjugate (ADC) candidates TUB-040 (NaPi2b target) and TUB-030 (5T4 target) into later-stage clinical evaluation in high‑need solid tumors.1
His role includes helping to expand Tubulis’ ADC pipeline beyond the current lead programs, leveraging the company’s proprietary ADC platform technologies.1
Tubulis’ recent significant capital raise (reported as a large Series C round of approximately $401 million in external coverage) is cited by the CEO as a key enabler for this next phase and the timing of Fuchs’ hire.14
Fuchs highlighted recent TUB-040 data presented at ESMO as underscoring Tubulis’ emergence as a leader in ADC development with potential to reshape treatment for patients with solid tumors.1
Over his three‑decade career, Fuchs has contributed to cancer biology, treatment, and prevention at leading institutions including Yale Cancer Center/Smilow Cancer Hospital, Dana‑Farber Cancer Institute, and Harvard Medical School.1
At Roche/Genentech, Fuchs drove portfolio growth and achieved global regulatory approvals for multiple therapies, including Lunsumio, Columvi, Polivy, Crovalimab, Tecentriq and Inavolisib.1
Fuchs has held advisory and board roles at various biotech companies and investment funds and has authored over 700 peer‑reviewed publications, reflecting broad influence in oncology R&D.1
Tubulis positions its technology as generating “uniquely matched” ADCs with superior biophysical properties, enabling durable on‑tumor delivery and long‑lasting anti‑tumor activity, with early clinical proof‑of‑concept shown in platinum‑resistant ovarian cancer.1
Sources:
1. https://www.businesswire.com/news/home/20260108544299/en/Tubulis-Appoints-Charles-Fuchs-MD-as-Chief-Medical-Officer-to-Lead-Clinical-Strategy-and-Pipeline-Development